148 related articles for article (PubMed ID: 36223747)
1. Cancer-specific T helper shared and neo-epitopes uncovered by expression of the MHC class II master regulator CIITA.
Hos BJ; Tondini E; Camps MGM; Rademaker W; van den Bulk J; Ruano D; Janssen GMC; de Ru AH; van den Elsen PJ; de Miranda NFCC; van Veelen PA; Ossendorp F
Cell Rep; 2022 Oct; 41(2):111485. PubMed ID: 36223747
[TBL] [Abstract][Full Text] [Related]
2. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
[TBL] [Abstract][Full Text] [Related]
3. CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine.
Accolla RS; Ramia E; Tedeschi A; Forlani G
Front Immunol; 2019; 10():1806. PubMed ID: 31417570
[TBL] [Abstract][Full Text] [Related]
4. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
5. The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease.
Stüve O; Youssef S; Slavin AJ; King CL; Patarroyo JC; Hirschberg DL; Brickey WJ; Soos JM; Piskurich JF; Chapman HA; Zamvil SS
J Immunol; 2002 Dec; 169(12):6720-32. PubMed ID: 12471103
[TBL] [Abstract][Full Text] [Related]
6. FBXO11 constitutes a major negative regulator of MHC class II through ubiquitin-dependent proteasomal degradation of CIITA.
Kasuga Y; Ouda R; Watanabe M; Sun X; Kimura M; Hatakeyama S; Kobayashi KS
Proc Natl Acad Sci U S A; 2023 Jun; 120(24):e2218955120. PubMed ID: 37279268
[TBL] [Abstract][Full Text] [Related]
7. Introduction of the CIITA gene into tumor cells produces exosomes with enhanced anti-tumor effects.
Lee YS; Kim SH; Cho JA; Kim CW
Exp Mol Med; 2011 May; 43(5):281-90. PubMed ID: 21464590
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun.
Kim D; Hoory T; Monie A; Ting JP; Hung CF; Wu TC
J Immunol; 2008 May; 180(10):7019-27. PubMed ID: 18453624
[TBL] [Abstract][Full Text] [Related]
9. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
[TBL] [Abstract][Full Text] [Related]
10. Activated human T cells accomplish MHC class II expression through T cell-specific occupation of class II transactivator promoter III.
Holling TM; van der Stoep N; Quinten E; van den Elsen PJ
J Immunol; 2002 Jan; 168(2):763-70. PubMed ID: 11777970
[TBL] [Abstract][Full Text] [Related]
11. Fowlpoxvirus recombinants coding for the CIITA gene increase the expression of endogenous MHC-II and Fowlpox Gag/Pro and Env SIV transgenes.
Bissa M; Forlani G; Zanotto C; Tosi G; De Giuli Morghen C; Accolla RS; Radaelli A
PLoS One; 2018; 13(1):e0190869. PubMed ID: 29385169
[TBL] [Abstract][Full Text] [Related]
12. Autoimmunity and inflammation are independent of class II transactivator type PIV-dependent class II major histocompatibility complex expression in peripheral tissues during collagen-induced arthritis.
Waldburger JM; Palmer G; Seemayer C; Lamacchia C; Finckh A; Christofilopoulos P; Baeten D; Reith W; Gabay C
Arthritis Rheum; 2011 Nov; 63(11):3354-63. PubMed ID: 21739421
[TBL] [Abstract][Full Text] [Related]
13. CIITA-Transduced Glioblastoma Cells Uncover a Rich Repertoire of Clinically Relevant Tumor-Associated HLA-II Antigens.
Forlani G; Michaux J; Pak H; Huber F; Marie Joseph EL; Ramia E; Stevenson BJ; Linnebacher M; Accolla RS; Bassani-Sternberg M
Mol Cell Proteomics; 2021; 20():100032. PubMed ID: 33592498
[TBL] [Abstract][Full Text] [Related]
14. Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation.
Soos JM; Krieger JI; Stüve O; King CL; Patarroyo JC; Aldape K; Wosik K; Slavin AJ; Nelson PA; Antel JP; Zamvil SS
Glia; 2001 Dec; 36(3):391-405. PubMed ID: 11746775
[TBL] [Abstract][Full Text] [Related]
15. MHC class II transactivator is an in vivo regulator of osteoclast differentiation and bone homeostasis co-opted from adaptive immunity.
Benasciutti E; Mariani E; Oliva L; Scolari M; Perilli E; Barras E; Milan E; Orfanelli U; Fazzalari NL; Campana L; Capobianco A; Otten L; Particelli F; Acha-Orbea H; Baruffaldi F; Faccio R; Sitia R; Reith W; Cenci S
J Bone Miner Res; 2014 Feb; 29(2):290-303. PubMed ID: 24038328
[TBL] [Abstract][Full Text] [Related]
16. Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response.
Ekkirala CR; Cappello P; Accolla RS; Giovarelli M; Romero I; Garrido C; Garcia-Lora AM; Novelli F
Pancreas; 2014 Oct; 43(7):1066-72. PubMed ID: 24987872
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
Li D; Qian L; Chen C; Shi M; Yu M; Hu M; Song L; Shen B; Guo N
J Immunol; 2009 Feb; 182(4):1799-809. PubMed ID: 19201831
[TBL] [Abstract][Full Text] [Related]
18. Critical role of the tumor suppressor tuberous sclerosis complex 1 in dendritic cell activation of CD4 T cells by promoting MHC class II expression via IRF4 and CIITA.
Pan H; O'Brien TF; Wright G; Yang J; Shin J; Wright KL; Zhong XP
J Immunol; 2013 Jul; 191(2):699-707. PubMed ID: 23776173
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the expression of MHC class I and II by class II transactivator (CIITA) in hematopoietic cells.
Liu A; Takahashi M; Toba K; Zheng Z; Hashimoto S; Nikkuni K; Furukawa T; Koike T; Aizawa Y
Hematol Oncol; 1999 Dec; 17(4):149-60. PubMed ID: 10725870
[TBL] [Abstract][Full Text] [Related]
20. CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells.
Meissner M; Whiteside TL; Kaufmann R; Seliger B
Arch Dermatol Res; 2009 Feb; 301(2):189-93. PubMed ID: 19104823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
